Blackstone-managed funds will cover as much as $1.5 billion of Pfizer's development costs for the experimental obesity drug berobenatide through 2028, under a co-funding agreement announced on Wednesday.

The deal shifts a substantial share of research and development spending for the investigational therapy — a monthly injection being studied for chronic weight management and obesity-related conditions — from Pfizer's own balance sheet to private capital. In exchange, Blackstone could receive milestone-linked payments from Pfizer, the companies said.

The payments hinge on two conditions: U.S. regulatory approval of monthly dosing of injectable berobenatide monotherapy (a monotherapy is a drug used alone, not in combination) for chronic weight management, and the achievement of certain commercial sales milestones. Any payments earned will be made over a multi-year period, according to the companies.

Who controls the drug?

Blackstone acquires no rights or ownership in berobenatide under the agreement. Pfizer retains full operational control and decision-making over the program, the companies said.

The investment comes from funds managed by Blackstone Life Sciences, alongside capital from BXPE, Blackstone's perpetual private equity strategy (a vehicle that does not require a fixed exit date for its holdings). The structure gives Pfizer external funding without diluting its ownership of a drug positioned at the center of its cardiometabolic ambitions.

What did the executives say?

Pfizer Chief Financial Officer Ceciile Guegan framed the deal as financial discipline rather than a cash shortage. "Our aim is to bring important new medicines to patients while taking a disciplined approach that pairs internal research investments with targeted investment from capital partners," Guegan said in a statement. "Today's announcement helps us advance our comprehensive obesity program and maintain the financial capacity and flexibility to invest in our broader pipeline across all therapeutic areas."

Nicholas Galakatos, global head of Blackstone Life Sciences, pointed to the scale of the development program. "We are pleased to further expand our relationship with Pfizer and support the broad and rigorous development of berobenatide as the anchor of Pfizer's cardiometabolic pipeline," Galakatos said in a statement.

How large is the clinical program?

Pfizer intends to run more than 20 studies covering obesity and related conditions during 2026, the company said. The berobenatide program alone includes:

• 10 ongoing and planned Phase 3 trials (the final stage of human testing before regulatory approval)
• Studies in knee osteoarthritis and obstructive sleep apnea, two obesity-related conditions
• Development both as a monotherapy and in combination with other peptides, including amylin analogs (a class of drugs that mimic a satiety hormone)

The breadth of the trial roster underlines why external funding appeals to Pfizer: obesity drug development now spans multiple indications beyond weight loss itself, and each Phase 3 trial carries significant cost.

Why does the deal matter?

The $1.5 billion commitment ranks among the larger external funding arrangements for a single investigational drug, and it arrives as competition in the obesity market intensifies. By capping its own exposure to berobenatide's development costs, Pfizer preserves capital for the rest of its pipeline while keeping every commercial right to the drug.

For Blackstone, the arrangement offers exposure to a late-stage obesity asset without the operational burden. The firm's returns depend on regulatory approval and sales performance — the same milestones Pfizer must hit for the drug to succeed.

The agreement covers R&D expenses between now and 2028, giving Pfizer a funded runway through the peak years of its Phase 3 program. The companies did not disclose the size of individual milestone payments.